达格列净及其抗心衰治疗的研究进展

Progress of dapagliflozin in treatment of heart failure

达格列净已被证实能在传统抗心衰标准治疗基础上,进一步减少射血分数降低的心衰(HFrEF)患者主要心血管不良事件发生的风险,现在抗心衰标准药物治疗已由过去“旧三联”进入“新四联”时代。近期的一些研究表明,包括达格列净在内的钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)甚至能降低射血分数保留心衰(HFpEF)患者的心衰死亡或住院的综合风险,这意味着这类心衰患者将得到明确且有效的药物治疗。该文综述了达格列净及其抗心衰治疗的发展过程及治疗现况。

Dapagliflozin can further reduce the risk of major adverse cardiovascular events in patients with heart failure with reduced ejection fraction(HFrEF)based on traditional anti-heart failure therapy.Currently,the standard anti-heart failure agents has been developed from the"past triple drugs"into the"new quadruple drugs".Recent studies have shown that sodium-glucose cotransporter-2 inhibitors(SGLT2i)including dapagliflozin can even reduce the combined risk of cardiovascular death or hospitalization in patients with heart failure with preserved ejection fraction,suggesting that they are effective for these patients.This paper reviews the development and current status of dapagliflozin in treatment of heart failure.